Which has better earnings and valuation, PTGX or GENB?

Generate Biomedicines has lower revenue, but higher earnings than Protagonist Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protagonist Therapeutics $46.02M 153.41 -$130.15M -$1.81 N/A Generate Biomedicines $30.30M 52.38 N/A N/A N/A

Does the media prefer PTGX or GENB?

In the previous week, Protagonist Therapeutics had 12 more articles in the media than Generate Biomedicines. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 2 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 1.03 beat Generate Biomedicines' score of 0.93 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GENB or TGTX?

TG Therapeutics has higher revenue and earnings than Generate Biomedicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Generate Biomedicines $30.30M 52.38 N/A N/A N/A TG Therapeutics $616.29M 12.30 $447.18M $2.86 17.31

Does the media prefer GENB or TGTX?

In the previous week, TG Therapeutics had 10 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat TG Therapeutics' score of 0.75 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SYRE or GENB?

Generate Biomedicines has higher revenue and earnings than Spyre Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyre Therapeutics $890K 7,882.93 -$155.20M -$2.08 N/A Generate Biomedicines $30.30M 52.38 N/A N/A N/A

Is SYRE or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Generate Biomedicines N/A N/A N/A

Does the media favor SYRE or GENB?

In the previous week, Spyre Therapeutics had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Spyre Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Spyre Therapeutics' score of 0.91 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LNTH or GENB?

Lantheus has higher revenue and earnings than Generate Biomedicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.41 $233.56M $4.15 25.19 Generate Biomedicines $30.30M 52.38 N/A N/A N/A

Does the media refer more to LNTH or GENB?

In the previous week, Lantheus had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Lantheus and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Lantheus' score of 0.63 indicating that Generate Biomedicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IMVT or GENB?

Generate Biomedicines has higher revenue and earnings than Immunovant. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Generate Biomedicines $30.30M 52.38 N/A N/A N/A

Is IMVT or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Generate Biomedicines N/A N/A N/A

Does the media refer more to IMVT or GENB?

In the previous week, Immunovant had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Immunovant and 2 mentions for Generate Biomedicines. Immunovant's average media sentiment score of 1.65 beat Generate Biomedicines' score of 0.93 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Generate Biomedicines (GENB) Competitors

$12.38 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$12.54 +0.16 (+1.29%)

As of 06/12/2026 07:55 PM Eastern

Compare

GENB vs. PTGX, TGTX, SYRE, LNTH, and IMVT

Should you buy Generate Biomedicines stock or one of its competitors? MarketBeat compares Generate Biomedicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Generate Biomedicines include Protagonist Therapeutics (PTGX), TG Therapeutics (TGTX), Spyre Therapeutics (SYRE), Lantheus (LNTH), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.

How does Generate Biomedicines compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Generate Biomedicines has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Generate Biomedicines' return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has lower revenue, but higher earnings than Protagonist Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	153.41	-$130.15M	-$1.81	N/A
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Protagonist Therapeutics had 12 more articles in the media than Generate Biomedicines. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 2 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 1.03 beat Generate Biomedicines' score of 0.93 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics currently has a consensus price target of $115.21, indicating a potential upside of 4.95%. Generate Biomedicines has a consensus price target of $25.40, indicating a potential upside of 105.17%. Given Generate Biomedicines' higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Protagonist Therapeutics beats Generate Biomedicines on 9 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to TG Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and TG Therapeutics (NASDAQ:TGTX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

TG Therapeutics has a net margin of 65.95% compared to Generate Biomedicines' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
TG Therapeutics	65.95%	88.73%	43.44%

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 105.17%. TG Therapeutics has a consensus target price of $52.50, suggesting a potential upside of 6.02%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, research analysts clearly believe Generate Biomedicines is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

TG Therapeutics has higher revenue and earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A
TG Therapeutics	$616.29M	12.30	$447.18M	$2.86	17.31

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, TG Therapeutics had 10 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for TG Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat TG Therapeutics' score of 0.75 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Generate Biomedicines on 8 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Spyre Therapeutics presently has a consensus price target of $91.33, indicating a potential upside of 13.05%. Generate Biomedicines has a consensus price target of $25.40, indicating a potential upside of 105.17%. Given Generate Biomedicines' higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has higher revenue and earnings than Spyre Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	7,882.93	-$155.20M	-$2.08	N/A
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A

In the previous week, Spyre Therapeutics had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Spyre Therapeutics and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Spyre Therapeutics' score of 0.91 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Spyre Therapeutics beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Lantheus had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Lantheus and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Lantheus' score of 0.63 indicating that Generate Biomedicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Generate Biomedicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.41	$233.56M	$4.15	25.19
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A

Lantheus presently has a consensus price target of $101.86, suggesting a potential downside of 2.55%. Generate Biomedicines has a consensus price target of $25.40, suggesting a potential upside of 105.17%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts plainly believe Generate Biomedicines is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Lantheus has a net margin of 18.05% compared to Generate Biomedicines' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Generate Biomedicines	N/A	N/A	N/A

99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Lantheus beats Generate Biomedicines on 8 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Generate Biomedicines (NASDAQ:GENB) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Generate Biomedicines has higher revenue and earnings than Immunovant.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Generate Biomedicines has a consensus target price of $25.40, suggesting a potential upside of 105.17%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, analysts plainly believe Generate Biomedicines is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Immunovant had 2 more articles in the media than Generate Biomedicines. MarketBeat recorded 4 mentions for Immunovant and 2 mentions for Generate Biomedicines. Immunovant's average media sentiment score of 1.65 beat Generate Biomedicines' score of 0.93 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Generate Biomedicines	N/A	N/A	N/A

Summary

Generate Biomedicines beats Immunovant on 5 of the 9 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.59B	$2.95B	$4.29B	$12.05B
Dividend Yield	N/A	15.26%	10.25%	5.67%
P/E Ratio	N/A	13.63	22.29	24.42
Price / Sales	52.38	3,138.67	159.46	109.90
Price / Cash	N/A	26.81	40.19	37.92
Price / Book	N/A	4.79	26.92	6.82
Net Income	N/A	-$39.47M	$116.61M	$337.56M
7 Day Performance	-3.13%	0.45%	0.25%	1.17%
1 Month Performance	-22.63%	0.62%	0.25%	3.16%
1 Year Performance	N/A	16.42%	14.23%	30.58%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	N/A	$12.38 flat	$25.40 +105.2%	N/A	$1.59B	$30.30M	N/A	312	Gap Up
PTGX Protagonist Therapeutics	1.5798 of 5 stars	$104.14 +6.2%	$115.21 +10.6%	+94.7%	$6.65B	$46.02M	N/A	120	Positive News
TGTX TG Therapeutics	2.2957 of 5 stars	$43.14 +5.3%	$52.50 +21.7%	+37.5%	$6.62B	$616.29M	15.13	290	Gap Down
SYRE Spyre Therapeutics	1.7052 of 5 stars	$74.54 +3.5%	$91.33 +22.5%	+367.3%	$6.48B	$890K	N/A	73	Gap Up
LNTH Lantheus	2.6753 of 5 stars	$99.74 -0.3%	$101.86 +2.1%	+34.3%	$6.48B	$1.54B	24.00	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, TGTX, SYRE, LNTH, and IMVT

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Summary

How does Generate Biomedicines compare to Lantheus?

Summary

How does Generate Biomedicines compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, TGTX, SYRE, LNTH, and IMVT

How does Generate Biomedicines compare to Protagonist Therapeutics?

Is PTGX or GENB more profitable?

Which has better earnings and valuation, PTGX or GENB?

Do insiders and institutionals have more ownership in PTGX or GENB?

Does the media prefer PTGX or GENB?

Do analysts recommend PTGX or GENB?

Summary

How does Generate Biomedicines compare to TG Therapeutics?

Is GENB or TGTX more profitable?

Do analysts rate GENB or TGTX?

Which has preferable earnings and valuation, GENB or TGTX?

Do insiders & institutionals have more ownership in GENB or TGTX?

Does the media prefer GENB or TGTX?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Do analysts prefer SYRE or GENB?

Is SYRE or GENB more profitable?

Which has better earnings & valuation, SYRE or GENB?

Does the media favor SYRE or GENB?

Do insiders and institutionals believe in SYRE or GENB?

Summary

How does Generate Biomedicines compare to Lantheus?

Does the media refer more to LNTH or GENB?

Which has preferable valuation and earnings, LNTH or GENB?

Do analysts prefer LNTH or GENB?

Is LNTH or GENB more profitable?

Do insiders & institutionals hold more shares of LNTH or GENB?

Summary

How does Generate Biomedicines compare to Immunovant?

Which has stronger earnings and valuation, IMVT or GENB?

Do institutionals & insiders believe in IMVT or GENB?

Do analysts prefer IMVT or GENB?

Does the media refer more to IMVT or GENB?

Is IMVT or GENB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools